Form 4: Imunon Executive Chairman Acquires Shares via Salary Grant

Executive Chairman Michael H. Tardugno acquired 4,089 shares of Imunon, Inc. common stock as compensation in lieu of cash salary.

Summary

• Executive Chairman Michael H. Tardugno acquired 4,089 shares of Imunon, Inc. (IMNN) common stock on June 5, 2026.
• The shares were issued at a price of $2.06 per share.
• The acquisition was made as a grant in lieu of cash for base salary.
• Following this transaction, the reporting person directly owns 12,838 shares of common stock.
• The reporting person also maintains an indirect holding of 4,622 shares held in an IRA.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of executive interests with shareholders through equity-based compensation.
• Demonstrates management's willingness to accept stock in lieu of cash, preserving company liquidity.

Negatives

• None identified in this filing.

Risks

• Market price volatility of IMNN common stock affecting the value of executive compensation.

Future Outlook

No specific forward-looking guidance provided in this disclosure.

Industry Context

StockSavvy.ai notes that equity-in-lieu-of-salary arrangements are common in the biotechnology sector, particularly among smaller-cap firms looking to conserve cash for R&D and clinical trial operations.

Comparison to Industry Standards

• The use of equity compensation for executives is standard practice in the early-stage biotech industry to align leadership with long-term value creation.
• The transaction size is relatively small and consistent with standard executive compensation adjustments.

Stakeholder Impact

• Minimal impact on shareholders as the transaction represents a standard compensation adjustment.

Key Dates

Keywords

Imunon, IMNN, Form 4, Insider Trading, Executive Compensation, Equity Grant